Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: A Phase 3 randomized clinical trial
JAMA Dermatol 2020;156:649–58. doi 10.1001/jamadermatol.2020.0723
Blauvelt et al. shows superior and sustained efficacy for risankizumab in maintaining skin clearance over time versus placebo upon withdrawal, alongside a favourable safety profile in chronic plaque psoriasis through a phase 3, randomised, double-blind, placebo-controlled study, assessing PASI 90 and sPGA score of 0/1 at Week 16.
Patients were randomised 1:4 to placebo and risankizumab at baseline, with the placebo group switched to risankizumab at Week 16. The second part of the study rerandomized the risankizumab to placebo, blinded risankizumab, or open risankizumab, while the placebo to risankizumab group were randomised to blinded or open risankizumab.
Keywords:
